Matches in SemOpenAlex for { <https://semopenalex.org/work/W2056570112> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W2056570112 startingPage "1906" @default.
- W2056570112 abstract "Background: Nintedanib, an intracellular inhibitor of tyrosine kinases, is in development for the treatment of idiopathic pulmonary fibrosis (IPF). The INPULSIS™ trials were two replicate 52-week, randomized, double-blind, placebo-controlled Phase III trials that investigated the efficacy and safety of nintedanib 150 mg twice daily in 1066 patients with IPF. Declines in forced vital capacity (FVC) % predicted of >5% and >10% in patients with IPF have been proposed as indicators of disease progression and have been associated with reduced survival. Aim: To determine the effect of nintedanib on changes in FVC % predicted in the INPULSIS™ trials. Methods: The proportions of patients with absolute and relative declines in FVC % predicted of >5% and >10% at week 52 in each INPULSIS™ trial were determined in a post-hoc analysis. Results: In each trial, a significantly greater proportion of patients in the placebo group had an absolute decline in FVC % predicted of >5% compared with the nintedanib group. In INPULSIS™-1, a significantly greater proportion of patients in the placebo group had an absolute decline in FVC % predicted of >10% compared with the nintedanib group; the difference between groups in INPULSIS™-2 was numerically in favour of nintedanib but did not reach statistical significance. In each trial, significantly greater proportions of patients in the placebo group had relative declines in FVC % predicted of >5% and >10% compared with the nintedanib group. Conclusion: In the INPULSIS™ trials, nintedanib reduced the proportion of patients with IPF who experienced disease progression as measured by categorical FVC decline." @default.
- W2056570112 created "2016-06-24" @default.
- W2056570112 creator A5014703126 @default.
- W2056570112 creator A5019441565 @default.
- W2056570112 creator A5021656163 @default.
- W2056570112 creator A5029218290 @default.
- W2056570112 creator A5071431376 @default.
- W2056570112 creator A5078029953 @default.
- W2056570112 creator A5087279007 @default.
- W2056570112 creator A5091576695 @default.
- W2056570112 date "2014-09-01" @default.
- W2056570112 modified "2023-09-26" @default.
- W2056570112 title "Reduction in disease progression with nintedanib in the INPULSIS™ trials" @default.
- W2056570112 hasPublicationYear "2014" @default.
- W2056570112 type Work @default.
- W2056570112 sameAs 2056570112 @default.
- W2056570112 citedByCount "0" @default.
- W2056570112 crossrefType "journal-article" @default.
- W2056570112 hasAuthorship W2056570112A5014703126 @default.
- W2056570112 hasAuthorship W2056570112A5019441565 @default.
- W2056570112 hasAuthorship W2056570112A5021656163 @default.
- W2056570112 hasAuthorship W2056570112A5029218290 @default.
- W2056570112 hasAuthorship W2056570112A5071431376 @default.
- W2056570112 hasAuthorship W2056570112A5078029953 @default.
- W2056570112 hasAuthorship W2056570112A5087279007 @default.
- W2056570112 hasAuthorship W2056570112A5091576695 @default.
- W2056570112 hasConcept C126322002 @default.
- W2056570112 hasConcept C142724271 @default.
- W2056570112 hasConcept C165637977 @default.
- W2056570112 hasConcept C204787440 @default.
- W2056570112 hasConcept C27081682 @default.
- W2056570112 hasConcept C2777714996 @default.
- W2056570112 hasConcept C2778341716 @default.
- W2056570112 hasConcept C2780171596 @default.
- W2056570112 hasConcept C3018587741 @default.
- W2056570112 hasConcept C535046627 @default.
- W2056570112 hasConcept C55520419 @default.
- W2056570112 hasConcept C71924100 @default.
- W2056570112 hasConceptScore W2056570112C126322002 @default.
- W2056570112 hasConceptScore W2056570112C142724271 @default.
- W2056570112 hasConceptScore W2056570112C165637977 @default.
- W2056570112 hasConceptScore W2056570112C204787440 @default.
- W2056570112 hasConceptScore W2056570112C27081682 @default.
- W2056570112 hasConceptScore W2056570112C2777714996 @default.
- W2056570112 hasConceptScore W2056570112C2778341716 @default.
- W2056570112 hasConceptScore W2056570112C2780171596 @default.
- W2056570112 hasConceptScore W2056570112C3018587741 @default.
- W2056570112 hasConceptScore W2056570112C535046627 @default.
- W2056570112 hasConceptScore W2056570112C55520419 @default.
- W2056570112 hasConceptScore W2056570112C71924100 @default.
- W2056570112 hasOpenAccess W2056570112 @default.
- W2056570112 hasRelatedWork W1757222072 @default.
- W2056570112 hasRelatedWork W1896745119 @default.
- W2056570112 hasRelatedWork W2038320582 @default.
- W2056570112 hasRelatedWork W2059459008 @default.
- W2056570112 hasRelatedWork W2098545954 @default.
- W2056570112 hasRelatedWork W2341412218 @default.
- W2056570112 hasRelatedWork W2462000645 @default.
- W2056570112 hasRelatedWork W2555363460 @default.
- W2056570112 hasRelatedWork W2556832538 @default.
- W2056570112 hasRelatedWork W2557106527 @default.
- W2056570112 hasRelatedWork W2561981946 @default.
- W2056570112 hasRelatedWork W2569832671 @default.
- W2056570112 hasRelatedWork W2769846020 @default.
- W2056570112 hasRelatedWork W2775753718 @default.
- W2056570112 hasRelatedWork W2777232717 @default.
- W2056570112 hasRelatedWork W2811389906 @default.
- W2056570112 hasRelatedWork W2901235303 @default.
- W2056570112 hasRelatedWork W2966144780 @default.
- W2056570112 hasRelatedWork W3107410078 @default.
- W2056570112 hasRelatedWork W2529939697 @default.
- W2056570112 hasVolume "44" @default.
- W2056570112 isParatext "false" @default.
- W2056570112 isRetracted "false" @default.
- W2056570112 magId "2056570112" @default.
- W2056570112 workType "article" @default.